GEN Exclusives

More »

GEN Poll

More »
Oct 31, 2011

Royalty/Revenue Monetization

A relatively small but growing number of drug developers are monetizing their royalties/revenues by selling off all or part of these income streams to investors. If done prior to launch, these deals can protect against downside risk of the product not being a commercial success. But royalty/revenue monetization is still a relatively expensive source of capital, compared to raising conventional debt, if that is a possibility. Click here for more pros and cons. The amount of capital provided for royalty/revenue monetization deals over the past five years has doubled since between 2000 and 2005. Tell us if you would tap into this source of capital.

Do you think entering royalty and revenue monetization transactions is a good strategy for a cash-strapped firm?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »